Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up.

摘要: The therapy for gastrointestinal stromal tumors (GIST) has changed significantly since the use of imatinib mesylate (IM). However, appropriate duration receiving adjuvant IM patients with high-risk GIST who underwent R0 resection is still controversial. From January 2005 to December 2014, 234 and were treated at our institution identified from a prospectively collected database. effect medication on long-term outcomes was analyzed. In this study, 140 cases male 94 female, mean age 57.5 ± 11.4 years. most common site stomach (103 cases, 44%), followed by small intestine (81 34.6%). 5 year recurrence-free survival (RFS) rate overall (OS) in whole groups 76.2 83.4%, respectively. patient’s prognosis improved due prolongation time treatment (P   0.05). patients, RFS rates 1-year group, 1–3-years 3–5-years group more than 5 years 36.5, 68.7, 71.2 90.8%, respectively, OS 36.7, 76.6, 84.0 97.4%, respectively (P < 0.001). addition, linear regression analysis showed that prolonged durations (P < 0.05). better those it less 5 years. Multivariate COX tumor located an independent risk factor, while protective factor prognosis. high treatment. To reduce recurrence improve survival, we suggest receive least